AdiaVita + Glutathione for Chronic Kidney Disease

Overseen By Larry Powalisz

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Adia Med of Winter Park LLC

Disqualifiers: Immunocompromised, Malignancy history, Dialysis, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 3

Duration: 3 months

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD). In this condition, the kidneys gradually lose their ability to filter blood as well as they should. The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects. Researchers will compare three groups. One group will receive AdiaVita plus glutathione. A second group will receive glutathione plus a placebo for AdiaVita. The third group will receive placebos for both treatments. A placebo looks like the real treatment but contains no active ingredients. This will help determine if the full treatment works better than the controls. Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate. Participants will be randomly assigned to one of the three treatment groups. They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period. The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring. Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria. This is a single-blind study, meaning participants will not know which treatment they receive. Participant safety is closely monitored by the research team and an independent board throughout the study.

Who Is on the Research Team?

Evan Thomas, MD, PhD

Principal Investigator

Adia Med of Winter Park LLC

Are You a Good Fit for This Trial?

Inclusion Criteria

I am willing to try experimental treatments and follow study instructions.

I am between 18 and 80 years old.

I have chronic kidney disease with moderate to severe reduced kidney function.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive monthly intravenous infusions and apply a skin spray twice daily at home for the first three months

3 months

3 visits (in-person) for infusions

Crossover

Certain participants in the control groups may switch to the active AdiaVita treatment if they meet safety criteria

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

Regular visits for blood tests and physical exams

What Are the Treatments Tested in This Trial?

Interventions

• AdiaVita

How Is the Trial Designed?

Group I: Stem Cell + Glutathione Experimental Treatment 3 Interventions

Group II: Glutathione Control (with Crossover) Active Control 3 Interventions

Group III: Placebo Control (with Crossover) Placebo Group 3 Interventions

Who Is Running the Clinical Trial?

Adia Med of Winter Park LLC

Lead Sponsor